One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome
HFA Vasen, M Abdirahman, R Brohet, AMJ Langers… - Gastroenterology, 2010 - Elsevier
BACKGROUND & AIMS: Two percent to 4% of all cases of colorectal cancer (CRC) are
associated with Lynch syndrome. Dominant clustering of CRC (non-Lynch syndrome) …
associated with Lynch syndrome. Dominant clustering of CRC (non-Lynch syndrome) …
Immunoglobulin coating of faecal bacteria in inflammatory bowel disease
LA Van der Waaij, FGM Kroese, A Visser… - European journal of …, 2004 - journals.lww.com
Objective An inappropriate mucosal immune response to the commensal bacterial flora may
play a role in the pathogenesis of inflammatory bowel disease (IBD). In this study we …
play a role in the pathogenesis of inflammatory bowel disease (IBD). In this study we …
Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels
BD Westerveld, G Pals, C Lamers, J Defize, JC Pronk… - Cancer, 1987 - Wiley Online Library
Gastric mucosal pepsinogen A phenotype, serum pepsinogen A level, serum pepsinogen C
level, serum pepsinogen A/pepsinogen C ratio, and serum gastrin level were evaluated as …
level, serum pepsinogen A/pepsinogen C ratio, and serum gastrin level were evaluated as …
[HTML][HTML] On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients
NKH de Boer, LJJ Derijks, LPL Gilissen… - World journal of …, 2005 - ncbi.nlm.nih.gov
AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with
6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel …
6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel …
Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients
NKH De Boer, PE Zondervan, LPL Gilissen… - Digestive and liver …, 2008 - Elsevier
BACKGROUND: The use of 6-thioguanine has been proposed as a rescue drug for
inflammatory bowel disease patients. Initial data on short-term efficacy and toxicity of 6 …
inflammatory bowel disease patients. Initial data on short-term efficacy and toxicity of 6 …
Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis
DP van Asseldonk, B Jharap, DJ Kuik… - Digestive and Liver …, 2011 - Elsevier
BACKGROUND: Thioguanine has been used for the treatment of inflammatory bowel
disease, in particular for patients who failed conventional thiopurine therapy. To date …
disease, in particular for patients who failed conventional thiopurine therapy. To date …
Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD) Relation to disease pattern and disease activity
J Broekroelofs, AHL Mulder, GF Nelis… - Digestive diseases and …, 1994 - Springer
Anti-neutrophil cytoplasmic antibodies producing a perinuclear fluorescence pattern on
ethanol-fixed granulocytes (p-ANCA) were found in 33 of 67 patients (49%) with ulcerative …
ethanol-fixed granulocytes (p-ANCA) were found in 33 of 67 patients (49%) with ulcerative …
High detection rate of adenomas in familial colorectal cancer
AE Van der Meulen-de Jong, H Morreau, M Becx… - Gut, 2011 - gut.bmj.com
Background and aims Subjects with one first-degree relative (FDR) with colorectal cancer
(CRC)< 50 years old or two FDRs with CRC have an increased risk for CRC (RR 4–6) …
(CRC)< 50 years old or two FDRs with CRC have an increased risk for CRC (RR 4–6) …
Qualitative and quantitative determinations of pepsinogen I in gastric cancer and premalignant changes of the stomach.
BD Westerveld, G Pals, J Defize, J Pronk… - Progress in Clinical …, 1985 - europepmc.org
Previous studies in rats have shown that stomach carcinogens cause a decrease of total
pepsinogen content and a decrease of the fastest pepsinogen isozymogen in gastric …
pepsinogen content and a decrease of the fastest pepsinogen isozymogen in gastric …
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux …
CJJ Mulder, BD Westerveld, JM Smit… - European journal of …, 2002 - journals.lww.com
Background Proton pump inhibitors (PPIs) have proved to be effective in treating reflux
oesophagitis. Until now, no study had compared the PPIs omeprazole Multiple Unit Pellet …
oesophagitis. Until now, no study had compared the PPIs omeprazole Multiple Unit Pellet …